---
id        : Hypoxia.E-TABM-948.1
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : DU-145 prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 24

control   :
    - 02 1.2 DU145 Control 24h
    - 04 1.4 DU145 Control 48h
    - 06 2.2 DU145 Control 24h
    - 08 2.4 DU145 Control 48h
    - 10 3.2 DU145 Control 24h
    - 12 3.4 DU145 Control 48h
perturbed :
    - 01 1.1 DU145 Hypoxia 24h
    - 05 2.1 DU145 Hypoxia 24h
    - 09 3.1 DU145 Hypoxia 24h

---
id        : Hypoxia.E-TABM-948.2
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : DU-145 prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 48

control   :
    - 02 1.2 DU145 Control 24h
    - 04 1.4 DU145 Control 48h
    - 06 2.2 DU145 Control 24h
    - 08 2.4 DU145 Control 48h
    - 10 3.2 DU145 Control 24h
    - 12 3.4 DU145 Control 48h
perturbed :
    - 03 1.3 DU145 Hypoxia 48h
    - 07 2.3 DU145 Hypoxia 48h
    - 11 3.3 DU145 Hypoxia 48h

---
id        : Hypoxia.E-TABM-948.3
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : PC-3 prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 24

control   :
    - 14 1.8 PC3 Control 24h
    - 16 1.10 PC3 Control 48h
    - 18 2.8 PC3 Control 24h
    - 20 2.10 PC3 Control 48h
    - 22 3.8 PC3 Control 24h
    - 24 3.10 PC3 Control 48h
perturbed :
    - 13 1.7 PC3 Hypoxia 24h
    - 17 2.7 PC3 Hypoxia 24h
    - 21 3.7 PC3 Hypoxia 24h

---
id        : Hypoxia.E-TABM-948.4
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : PC-3 prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 24

control   :
    - 14 1.8 PC3 Control 24h
    - 16 1.10 PC3 Control 48h
    - 18 2.8 PC3 Control 24h
    - 20 2.10 PC3 Control 48h
    - 22 3.8 PC3 Control 24h
    - 24 3.10 PC3 Control 48h
perturbed :
    - 15 1.9 PC3 Hypoxia 48h
    - 19 2.9 PC3 Hypoxia 48h
    - 23 3.9 PC3 Hypoxia 48h

---
id        : Hypoxia.E-TABM-948.5
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : LNCaP prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 24

control   :
    - 26 1.14 LNCaP Control 24h
    - 28 1.16 LNCaP Control 48h
    - 30 2.14 LNCaP Control 24h
    - 32 2.16 LNCaP Control 48h
    - 34 3.14 LNCaP Control 24h
    - 36 3.16 LNCaP Control 48h
perturbed :
    - 25 1.13 LNCaP Hypoxia 24h
    - 29 2.13 LNCaP Hypoxia 24h
    - 33 3.13 LNCaP Hypoxia 24h

---
id        : Hypoxia.E-TABM-948.6
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : LNCaP prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 48

control   :
    - 26 1.14 LNCaP Control 24h
    - 28 1.16 LNCaP Control 48h
    - 30 2.14 LNCaP Control 24h
    - 32 2.16 LNCaP Control 48h
    - 34 3.14 LNCaP Control 24h
    - 36 3.16 LNCaP Control 48h
perturbed :
    - 27 1.15 LNCaP Hypoxia 48h
    - 31 2.15 LNCaP Hypoxia 48h
    - 35 3.15 LNCaP Hypoxia 48h

---
id        : Hypoxia.E-TABM-948.7
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : 22RV1 prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 24

control   :
    - 38 1.20 22RV1 Control 24h
    - 40 1.22 22RV1 Control 48h
    - 42 2.20 22RV1 Control 24h
    - 44 2.22 22RV1 Control 48h
    - 46 3.20 22RV1 Control 24h
    - 48 3.22 22RV1 Control 48h
perturbed :
    - 37 1.19 22RV1 Hypoxia 24h
    - 41 2.19 22RV1 Hypoxia 24h
    - 45 3.19 22RV1 Hypoxia 24h

---
id        : Hypoxia.E-TABM-948.8
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : 22RV1 prostate cancer cell line
treatment : hypoxia
effect    : activating
hours     : 48

control   :
    - 38 1.20 22RV1 Control 24h
    - 40 1.22 22RV1 Control 48h
    - 42 2.20 22RV1 Control 24h
    - 44 2.22 22RV1 Control 48h
    - 46 3.20 22RV1 Control 24h
    - 48 3.22 22RV1 Control 48h
perturbed :
    - 39 1.21 22RV1 Hypoxia 48h
    - 43 2.21 22RV1 Hypoxia 48h
    - 47 3.21 22RV1 Hypoxia 48h

---
id        : Hypoxia.E-TABM-948.9
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : primary prostate cells
treatment : hypoxia
effect    : activating
hours     : 24

control   :
    - 50 1.26 PrEC-4 P6 Control 24h
    - 52 1.28 PrEC-4 P6 Control 48h
    - 54 2.26 PrEC-4 P6 Control 24h
    - 56 2.28 PrEC-4 P6 Control 48h
    - 58 3.26 PrEC-4 P6 Control 24h
    - 60 3.28 PrEC-4 P6 Control 48h
    - 64 2.32 PrEC-2 P4 Control 24h
    - 66 2.34 PrEC-2 P4 Control 48h
    - 68 1.38 PrrEC-5 P4 Control 24h
    - 70 3.38 PrEC-5 P3 Control 24h
    - 72 3.40 PrEC-5 P3 Control 48h
    - 74 1.44 PrEC-3 P3 Control 24h
    - 76 1.46 PrEC-3 P3 Control 48h
perturbed :
    - 49 1.25 PrEC-4 P6 Hypoxia 24h
    - 53 2.25 PrEC-4 P6 Hypoxia 24h
    - 57 3.25 PrEC-4 P6 Hypoxia 24h
    - 63 2.31 PrEC-2 P4 Hypoxia 24h
    - 69 3.37 PrEC-5 P3 Hypoxia 24h
    - 73 1.43 PrEC-3 P3 Hypoxia 24h

---
id        : Hypoxia.E-TABM-948.10
accession : E-TABM-948
platform  : A-AFFY-44
pathway   : Hypoxia
cells     : primary prostate cells
treatment : hypoxia
effect    : activating
hours     : 48

control   :
    - 50 1.26 PrEC-4 P6 Control 24h
    - 52 1.28 PrEC-4 P6 Control 48h
    - 54 2.26 PrEC-4 P6 Control 24h
    - 56 2.28 PrEC-4 P6 Control 48h
    - 58 3.26 PrEC-4 P6 Control 24h
    - 60 3.28 PrEC-4 P6 Control 48h
    - 64 2.32 PrEC-2 P4 Control 24h
    - 66 2.34 PrEC-2 P4 Control 48h
    - 68 1.38 PrrEC-5 P4 Control 24h
    - 70 3.38 PrEC-5 P3 Control 24h
    - 72 3.40 PrEC-5 P3 Control 48h
    - 74 1.44 PrEC-3 P3 Control 24h
    - 76 1.46 PrEC-3 P3 Control 48h
perturbed :
    - 51 1.27 PrEC-4 P6 Hypoxia 48h
    - 55 2.27 PrEC-4 P6 Hypoxia 48h
    - 59 3.27 PrEC-4 P6 Hypoxia 48h
    - 65 2.33 PrEC-2 P4 Hypoxia 48h
    - 71 3.39 PrEC-5 P3 Hypoxia 48h
    - 75 1.45 PrEC-3 P3 Hypoxia 48h
...
